In this issue
The European Society for Medical Oncology (ESMO) Congress 2025 featured important discussions on optimising treatment strategies for patients with ER+/HER2- advanced/metastatic breast cancer. In this symposium, leading oncologists explored evolving second-line and beyond approaches following CDK4/6 inhibitor therapy, emphasising biomarker-driven decisions and the critical role of ESR1 mutation testing in guiding therapeutic choices.
Rate this content's potential impact on patient outcomes
Average rating 5 / 5. Vote count: 1
No votes so far! Be the first to rate this content.
Latest articles
All articles



We’ve noticed you’re accessing
from North/South America.
from North/South America.